Lazaroids

CNS pharmacology and current research

Wayne Clark, J. Samantha Hazel, Bruce M. Coull

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The 21-aminosteroids (lazaroids) are inhibitors of lipid membrane peroxidation and appear to function as oxygen free radical scavengers. The therapeutic potential of the lazaroid tirilazad mesylate has been extensively studied in several CNS disorders. Tirilazad and related compounds have been found to be highly beneficial in spinal cord trauma. Spinal cord injury studies utilising tirilazad are currently underway to determine the optimal combination of medications. Tirilazad has also been found to be beneficial in experimental head injury models, however current clinical studies have failed to confirm this efficacy, due in part to difficulties in obtaining therapeutic drug concentrations. Clinical studies using tirilazad in subarachnoid haemorrhage have been more promising. It has been shown to be beneficial in terms of reducing vasospasm and cerebral infarction associated with subarachnoid haemorrhage, and has now been approved in several European countries in this indication. Results from US studies are expected shortly. Finally, tirilazad has also been extensively tested in a variety of stroke models. Although it appears to be highly beneficial in experimental models, the clinical studies to date have failed to confirm this efficacy. Again, this failure appears to be due largely to inadequate drug concentrations having so far been tested.

Original languageEnglish (US)
Pages (from-to)971-983
Number of pages13
JournalDrugs
Volume50
Issue number6
StatePublished - Dec 1995

Fingerprint

Pharmacology
Research
Subarachnoid Hemorrhage
Spinal Cord Injuries
Free Radical Scavengers
Cerebral Infarction
Membrane Lipids
Craniocerebral Trauma
Pharmaceutical Preparations
tirilazad
Reactive Oxygen Species
Theoretical Models
Stroke
Oxygen
Therapeutics
Clinical Studies

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Toxicology

Cite this

Clark, W., Hazel, J. S., & Coull, B. M. (1995). Lazaroids: CNS pharmacology and current research. Drugs, 50(6), 971-983.

Lazaroids : CNS pharmacology and current research. / Clark, Wayne; Hazel, J. Samantha; Coull, Bruce M.

In: Drugs, Vol. 50, No. 6, 12.1995, p. 971-983.

Research output: Contribution to journalArticle

Clark, W, Hazel, JS & Coull, BM 1995, 'Lazaroids: CNS pharmacology and current research', Drugs, vol. 50, no. 6, pp. 971-983.
Clark W, Hazel JS, Coull BM. Lazaroids: CNS pharmacology and current research. Drugs. 1995 Dec;50(6):971-983.
Clark, Wayne ; Hazel, J. Samantha ; Coull, Bruce M. / Lazaroids : CNS pharmacology and current research. In: Drugs. 1995 ; Vol. 50, No. 6. pp. 971-983.
@article{a7d4b46f03584d21a972674526493b4c,
title = "Lazaroids: CNS pharmacology and current research",
abstract = "The 21-aminosteroids (lazaroids) are inhibitors of lipid membrane peroxidation and appear to function as oxygen free radical scavengers. The therapeutic potential of the lazaroid tirilazad mesylate has been extensively studied in several CNS disorders. Tirilazad and related compounds have been found to be highly beneficial in spinal cord trauma. Spinal cord injury studies utilising tirilazad are currently underway to determine the optimal combination of medications. Tirilazad has also been found to be beneficial in experimental head injury models, however current clinical studies have failed to confirm this efficacy, due in part to difficulties in obtaining therapeutic drug concentrations. Clinical studies using tirilazad in subarachnoid haemorrhage have been more promising. It has been shown to be beneficial in terms of reducing vasospasm and cerebral infarction associated with subarachnoid haemorrhage, and has now been approved in several European countries in this indication. Results from US studies are expected shortly. Finally, tirilazad has also been extensively tested in a variety of stroke models. Although it appears to be highly beneficial in experimental models, the clinical studies to date have failed to confirm this efficacy. Again, this failure appears to be due largely to inadequate drug concentrations having so far been tested.",
author = "Wayne Clark and Hazel, {J. Samantha} and Coull, {Bruce M.}",
year = "1995",
month = "12",
language = "English (US)",
volume = "50",
pages = "971--983",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Lazaroids

T2 - CNS pharmacology and current research

AU - Clark, Wayne

AU - Hazel, J. Samantha

AU - Coull, Bruce M.

PY - 1995/12

Y1 - 1995/12

N2 - The 21-aminosteroids (lazaroids) are inhibitors of lipid membrane peroxidation and appear to function as oxygen free radical scavengers. The therapeutic potential of the lazaroid tirilazad mesylate has been extensively studied in several CNS disorders. Tirilazad and related compounds have been found to be highly beneficial in spinal cord trauma. Spinal cord injury studies utilising tirilazad are currently underway to determine the optimal combination of medications. Tirilazad has also been found to be beneficial in experimental head injury models, however current clinical studies have failed to confirm this efficacy, due in part to difficulties in obtaining therapeutic drug concentrations. Clinical studies using tirilazad in subarachnoid haemorrhage have been more promising. It has been shown to be beneficial in terms of reducing vasospasm and cerebral infarction associated with subarachnoid haemorrhage, and has now been approved in several European countries in this indication. Results from US studies are expected shortly. Finally, tirilazad has also been extensively tested in a variety of stroke models. Although it appears to be highly beneficial in experimental models, the clinical studies to date have failed to confirm this efficacy. Again, this failure appears to be due largely to inadequate drug concentrations having so far been tested.

AB - The 21-aminosteroids (lazaroids) are inhibitors of lipid membrane peroxidation and appear to function as oxygen free radical scavengers. The therapeutic potential of the lazaroid tirilazad mesylate has been extensively studied in several CNS disorders. Tirilazad and related compounds have been found to be highly beneficial in spinal cord trauma. Spinal cord injury studies utilising tirilazad are currently underway to determine the optimal combination of medications. Tirilazad has also been found to be beneficial in experimental head injury models, however current clinical studies have failed to confirm this efficacy, due in part to difficulties in obtaining therapeutic drug concentrations. Clinical studies using tirilazad in subarachnoid haemorrhage have been more promising. It has been shown to be beneficial in terms of reducing vasospasm and cerebral infarction associated with subarachnoid haemorrhage, and has now been approved in several European countries in this indication. Results from US studies are expected shortly. Finally, tirilazad has also been extensively tested in a variety of stroke models. Although it appears to be highly beneficial in experimental models, the clinical studies to date have failed to confirm this efficacy. Again, this failure appears to be due largely to inadequate drug concentrations having so far been tested.

UR - http://www.scopus.com/inward/record.url?scp=0028805686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028805686&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 971

EP - 983

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 6

ER -